

**Staphylococcus aureus - VRS3a**  
Other designations ( HIP13170 )

Demographic Information:			
Country/State:	United States / New York	Date of Isolation:	03/17/2004
Patient Age:	64 Year(s)	Gender:	Female
Patient Location:	Long-term care facility	Patient Service:	N/A
Culture Source:	Urine		
Literature Citation:	CDC. Brief report: vancomycin-resistant Staphylococcus aureus - New York, 2004. MMWR April 23, 2004;53(15):322-323.		
Donor Reported MIC Results (ug/ml)	Vancomycin = 64	Teicoplanin = 16	
Comment:	VRS3a is in most aspects the same as VRS3b, but the vancomycin resistant phenotype for VRS3a is less stable than that of VRS3b. For stability purposes, it is recommended that VRS3a be subcultured in the presence of vancomycin.		
Repositories:	Glycopeptide Resistant Staphylococci		

**NARSA Antimicrobial Susceptibility Data for Glycopeptides**

Drug	Broth Microdilution		<sup>a</sup> Conventional Etest 0.5 McFarland Std		<sup>b</sup> Modified Etest 2 McFarland Std		<sup>c</sup> BHI Agar Screen	Disk Diffusion	
	MIC <del>ug/ml</del> µg/mL	CLSI Interpretn	MIC µg/ml	CLSI Interpretn	MIC µg/ml	CLSI Interpretn		Zone diam. (mm)	CLSI Interpretn
<b>Vancomycin:</b>	> 32	R	> 256	R	> 256	R	CG(24)	6	NS
<b>Teicoplanin:</b>	= 16	I	= 96	R	> 256	R		11	I

S = Susceptible; R = Resistant; NS = Not Susceptible; I = Intermediate; N/A = Not Available P = Pending results

NARSA Antimicrobial Profile for Other Antimicrobial Agents			Molecular Characterization Data	
Drug	MIC <del>ug/ml</del> µg/mL	CLSI Interpretn	PCR	Result
<b>Ciprofloxacin</b>	> 16	R	<b>vanA</b>	POSITIVE
<b>Clindamycin</b>	> 4	R	<b>vanB</b>	NEGATIVE
<b>Daptomycin</b>	= 0.25	N/A	<b>vanC1</b>	NEGATIVE
<b>Erythromycin</b>	> 8	R	<b>vanC2</b>	NEGATIVE
<b>Gentamicin</b>	> 16	R	<b>vanD</b>	NEGATIVE
<b>Linezolid</b>	= 2	S	<b>vanE</b>	NEGATIVE
<b>Oxacillin</b>	> 16	R	<b>mecA</b>	POSITIVE
<b>Penicillin</b>	> 2	R		
<b>Quinupristin/dalfopristin</b>	= 0.5	S		
<b>Trimeth/sulfa</b>	<= 0.25/4.75	S		